BR112022015579A2 - Composições para tratamento de doenças oculares - Google Patents

Composições para tratamento de doenças oculares

Info

Publication number
BR112022015579A2
BR112022015579A2 BR112022015579A BR112022015579A BR112022015579A2 BR 112022015579 A2 BR112022015579 A2 BR 112022015579A2 BR 112022015579 A BR112022015579 A BR 112022015579A BR 112022015579 A BR112022015579 A BR 112022015579A BR 112022015579 A2 BR112022015579 A2 BR 112022015579A2
Authority
BR
Brazil
Prior art keywords
eye diseases
edonentan
agent
compositions
treatment
Prior art date
Application number
BR112022015579A
Other languages
English (en)
Portuguese (pt)
Inventor
Gurkan Sevgi
Ding Zhongli
Floyd David
Original Assignee
Perfuse Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Perfuse Therapeutics Inc filed Critical Perfuse Therapeutics Inc
Publication of BR112022015579A2 publication Critical patent/BR112022015579A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR112022015579A 2020-02-06 2021-02-03 Composições para tratamento de doenças oculares BR112022015579A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062971002P 2020-02-06 2020-02-06
US202063010212P 2020-04-15 2020-04-15
PCT/US2021/016414 WO2021158663A1 (en) 2020-02-06 2021-02-03 Compositions for treatment of ocular diseases

Publications (1)

Publication Number Publication Date
BR112022015579A2 true BR112022015579A2 (pt) 2022-10-11

Family

ID=77200537

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022015579A BR112022015579A2 (pt) 2020-02-06 2021-02-03 Composições para tratamento de doenças oculares

Country Status (11)

Country Link
US (2) US11873279B2 (https=)
EP (1) EP4100406A4 (https=)
JP (2) JP2023512763A (https=)
KR (1) KR20220143685A (https=)
CN (1) CN115103842A (https=)
AU (1) AU2021217358A1 (https=)
BR (1) BR112022015579A2 (https=)
CA (1) CA3168810A1 (https=)
IL (1) IL294873A (https=)
MX (1) MX2022009677A (https=)
WO (1) WO2021158663A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4050997A4 (en) * 2019-10-30 2022-11-30 Perfuse Therapeutics, Inc. TREATMENT OF EYE DISEASES USING ENDOTHELIN RECEPTOR ANTAGONISTS
CA3168810A1 (en) 2020-02-06 2021-08-12 Perfuse Therapeutics, Inc. Compositions for treatment of ocular diseases
CA3218398A1 (en) * 2021-04-30 2022-11-03 Perfuse Therapeutics, Inc. Treatment of ocular diseases using endothelin receptor antagonists
EP4329753A4 (en) 2021-04-30 2025-02-26 Perfuse Therapeutics, Inc. PHARMACEUTICAL COMPOSITIONS AND INTRAVITREAL DRUG DELIVERY SYSTEMS FOR THE TREATMENT OF EYE DISEASES
WO2025137005A1 (en) * 2023-12-20 2025-06-26 Perfuse Therapeutics, Inc. Methods of preparing drug delivery systems for the treatment of ocular diseases
WO2025137007A1 (en) * 2023-12-20 2025-06-26 Perfuse Therapeutics, Inc. Methods of preparing drug delivery systems for the treatment of ocular diseases

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4282793A (en) 1992-04-10 1993-11-18 State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University A microneedle for injection of ocular blood vessels
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
US6639082B2 (en) 2000-10-17 2003-10-28 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
JP2004525890A (ja) 2001-02-02 2004-08-26 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング ピラゾロ［４，３−ｄ］ピリミジンおよびエンドセリンレセプターアンタゴニストまたはチエノピリミジンおよびエンドセリンレセプターアンタゴニストを含む医薬製剤
US20030176356A1 (en) * 2001-04-24 2003-09-18 University Of North Texas Health Science Center Endothelin antagonists and endothelin-converting enzyme inhibitors for the treatment of glaucoma
GB0122318D0 (en) 2001-09-14 2001-11-07 Novartis Ag Organic compounds
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
BRPI1013904A2 (pt) 2009-04-30 2016-07-19 Univ Midwestern método e composição para tratar cetoacidose diabética
US20110082151A1 (en) 2009-06-12 2011-04-07 Auspex Pharmaceuticals, Inc. Sulfonylurea modulators of endothelin receptor
KR20130050939A (ko) 2010-04-12 2013-05-16 가부시키가이샤 아루떼꾸 우에노 망막 질환의 치료 방법 및 이를 위한 안과용 조성물
MX390909B (es) 2013-12-19 2025-03-21 Tassos Georgiou Composiciones de acidos grasos omega 3 para tratar enfermedades que implican daños al sistema nervioso.
MX2016009331A (es) * 2014-01-23 2016-10-26 Akebia Therapeutics Inc Composiciones y metodos para tratar enfermedades oculares.
ES2584534B1 (es) * 2015-03-27 2017-03-13 Retinset, S.L. Formulación tópica oftálmica de bosentan
CN107921036A (zh) 2015-05-29 2018-04-17 优势医疗公司 用于减少视力丧失的组合物和方法
JP6745594B2 (ja) * 2015-11-26 2020-08-26 持田製薬株式会社 ピラゾール誘導体の塩の結晶
WO2017217967A1 (en) 2016-06-13 2017-12-21 Noveome Biotherapeutics, Inc. Novel methods for delivering therapeutic agents to the eye via nasal passages
WO2018185516A1 (en) * 2017-04-05 2018-10-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy
EP3642214A2 (en) 2017-06-19 2020-04-29 Gangadhara Ganapati Nicotinamide riboside derivatives and their uses
JP2020528082A (ja) 2017-07-17 2020-09-17 ロイズマン，キース 加齢黄斑変性と他の眼疾患の治療用の細胞透過性ペプチドを使用する治療薬の局所送達
JP7134983B2 (ja) * 2017-09-15 2022-09-12 持田製薬株式会社 テトラヒドロナフチルウレア誘導体の結晶
WO2019210194A1 (en) 2018-04-26 2019-10-31 Vitrisa Therapeutics, Inc. Pegylated compositions for ocular use, and methods thereof
EP4050997A4 (en) 2019-10-30 2022-11-30 Perfuse Therapeutics, Inc. TREATMENT OF EYE DISEASES USING ENDOTHELIN RECEPTOR ANTAGONISTS
CA3168810A1 (en) 2020-02-06 2021-08-12 Perfuse Therapeutics, Inc. Compositions for treatment of ocular diseases

Also Published As

Publication number Publication date
CN115103842A (zh) 2022-09-23
US11873279B2 (en) 2024-01-16
MX2022009677A (es) 2022-09-09
WO2021158663A1 (en) 2021-08-12
JP2023512763A (ja) 2023-03-29
JP2025120268A (ja) 2025-08-15
US20240109876A1 (en) 2024-04-04
EP4100406A1 (en) 2022-12-14
EP4100406A4 (en) 2023-07-05
US20230120974A1 (en) 2023-04-20
CA3168810A1 (en) 2021-08-12
KR20220143685A (ko) 2022-10-25
IL294873A (en) 2022-09-01
AU2021217358A1 (en) 2022-09-08

Similar Documents

Publication Publication Date Title
BR112022015579A2 (pt) Composições para tratamento de doenças oculares
Grob et al. Management of mydriasis and pain in cataract and intraocular lens surgery: review of current medications and future directions
MX2022005063A (es) Tratamiento de enfermedades oculares con antagonistas de receptor de endotelina.
Hamada et al. Childhood blepharokeratoconjunctivitis: characterising a severe phenotype in white adolescents
BR112015001158A2 (pt) formulação oftálmica e respectivo uso e método para melhorar, reduzir ou tratar presbiopia
NZ588938A (en) Sustained release delivery of active agents to treat glaucoma and ocular hypertension
MX2020009132A (es) Composiciones farmaceuticas que comprenden nebivolol.
Vajpayee et al. Intrastromal fluid drainage with air tamponade: anterior segment optical coherence tomography guided technique for the management of acute corneal hydrops
ECSP22086300A (es) Composiciones que comprenden nanopartículas, método de elaboración y usos de las mismas
Guo et al. Scleral cross-linking in form-deprivation myopic guinea pig eyes leads to glaucomatous changes
BR112021023251A2 (pt) Tratamento da doença ocular
Karatas et al. Intravitreal ranibizumab versus intravitreal ranibizumab combined with posterior subtenon triamcinolone acetonide in diabetic macular edema
MX2020011535A (es) Formulacion de gotas para ojos y metodos para la liberacion sostenida de medicamento a la retina.
Arenas-Archila et al. Intra-lesional injection of betamethasone for the treatment of symptomatic pinguecula
Belkin et al. Direct trans-scleral selective laser trabeculoplasty (SLT) without a gonioscopy lens
Mortensen Corneal ectasia after PRK
Di et al. Comparison of the Clinical Outcomes between Combined Femtosecond Laser‐Assisted In Situ Keratomileusis and Corneal Cross Linking versus Combined Small‐Incision Lenticule Extraction and Corneal Cross Linking
AR056092A1 (es) Tratamiento de inflamaciones y anomalias vasculares oftalmologicas
Kazanova et al. Analysis of glaucoma process progression rates depending on various treatment non-compliance scenarios
Erichev et al. Selective sympathomimetics in monoand combination glaucoma therapy
Filatova et al. The effectiveness of additional medical management of patients in the early stages after reconstructive interventions on the auxiliary apparatus of the eye: assessment of changes in the tissues of the ocular surface and eyelids
Ali et al. Correlation between serum 25-hydroxyvitamin D levels and VEP and OCT in patients with primary open-angle glaucoma
Ho et al. Long-term natural course of lattice degeneration of the retina in high myopic eyes-A ten-year long term study.
Lovpache Using a fixed combination Dorsopt Plus in patients with various clinical forms of primary open angle glaucoma: the results of an 18-month follow-up
Iomdina Drug therapy of magnesium deficiency in patients with primary open angle glaucoma (POAG)

Legal Events

Date Code Title Description
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07D 413/12 , C07D 413/14 , C07D 413/00

Ipc: C07D 413/12 (2006.01), C07D 413/14 (2006.01), C07D

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]